TY - JOUR
T1 - Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors
AU - Danilova, Ludmila
AU - Wang, Hao
AU - Sunshine, Joel
AU - Kaunitz, Genevieve J.
AU - Cottrell, Tricia R.
AU - Xu, Haiying
AU - Esandrio, Jessica
AU - Anders, Robert A.
AU - Cope, Leslie
AU - Pardoll, Drew M.
AU - Drake, Charles G.
AU - Taube, Janis M.
N1 - Funding Information:
We thank Drs. Jeffrey Sosman and Matthew Hellmann for helpful discussions. This work was supported by the Dermatology Foundation and the W.W. Smith Foundation (J.M.T.); the Melanoma Research Alliance (J.M.T. and D.M.P.); Bristol-Myers Squibb (J.M.T., R.A.A., and D.M.P.); 5′ Diagnostics (R.A.A.); Sidney Kimmel Cancer Center Core Grant P30 CA006973 (to J.M.T., D.M.P., C.G.D., H.W., and L.D.); the National Cancer Institute NIH Grant R01 CA142779 (to J.M.T. and D.M.P.); NIH Grant T32 CA193145 (to T.R.C.); the Commonwealth Foundation (D.M.P.); and Moving for Melanoma of Delaware (J.M.T. and D.M.P.). The authors were also supported by the Bloomberg-Kimmel Institute for Cancer Immunotherapy and a Stand Up To Cancer-Cancer Research Institute Cancer Immunology Translational Cancer Research Grant (SU2C-AACR-DT1012). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.
Publisher Copyright:
© 2016, National Academy of Sciences. All rights reserved.
PY - 2016/11/29
Y1 - 2016/11/29
N2 - Programmed cell death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint blockade has led to remarkable and durable objective responses in a number of different tumor types. A better understanding of factors associated with the PD-1/PD-L axis expression is desirable, as it informs their potential role as prognostic and predictive biomarkers and may suggest rational treatment combinations. In the current study, we analyzed PD-L1, PD-L2, PD-1, and cytolytic activity (CYT) expression, as well as mutational density from melanoma and eight other solid tumor types using The Cancer Genome Atlas database. We found that in some tumor types, PD-L2 expression is more closely linked to Th1/IFNG expression and PD-1 and CD8 signaling than PD-L1. In contrast, mutational load was not correlated with a Th1/IFNG gene signature in any tumor type. PD-L1, PD-L2, PD-1, CYT expression, and mutational density are all positive prognostic features in melanoma, and conditional inference modeling revealed PD-1/CYT expression (i.e., an inflamed tumor microenvironment) as the most impactful feature, followed by mutational density. This study elucidates the highly interdependent nature of these parameters, and also indicates that future biomarkers for anti-PD-1/PD-L1 will benefit from tumor-type-specific, integrated, mRNA, protein, and genomic approaches.
AB - Programmed cell death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint blockade has led to remarkable and durable objective responses in a number of different tumor types. A better understanding of factors associated with the PD-1/PD-L axis expression is desirable, as it informs their potential role as prognostic and predictive biomarkers and may suggest rational treatment combinations. In the current study, we analyzed PD-L1, PD-L2, PD-1, and cytolytic activity (CYT) expression, as well as mutational density from melanoma and eight other solid tumor types using The Cancer Genome Atlas database. We found that in some tumor types, PD-L2 expression is more closely linked to Th1/IFNG expression and PD-1 and CD8 signaling than PD-L1. In contrast, mutational load was not correlated with a Th1/IFNG gene signature in any tumor type. PD-L1, PD-L2, PD-1, CYT expression, and mutational density are all positive prognostic features in melanoma, and conditional inference modeling revealed PD-1/CYT expression (i.e., an inflamed tumor microenvironment) as the most impactful feature, followed by mutational density. This study elucidates the highly interdependent nature of these parameters, and also indicates that future biomarkers for anti-PD-1/PD-L1 will benefit from tumor-type-specific, integrated, mRNA, protein, and genomic approaches.
KW - Melanoma
KW - Mutational load
KW - PD-1
KW - PD-L1
KW - PD-L2
UR - http://www.scopus.com/inward/record.url?scp=84999142201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84999142201&partnerID=8YFLogxK
U2 - 10.1073/pnas.1607836113
DO - 10.1073/pnas.1607836113
M3 - Article
C2 - 27837027
AN - SCOPUS:84999142201
SN - 0027-8424
VL - 113
SP - E7769-E7777
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 48
ER -